España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
InnoCan Pharma
INNPF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.1143
At close: Feb 18, 2:40 PM EDT
Get Report
Comment
InnoCan Pharma (INNPF) Forecast
News
Earnings
InnoCan Pharma (INNPF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for InnoCan Pharma (OTC:INNPF) Stock
InnoCan Pharma Stock (OTC: INNPF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 21, 2024
Cannabinoid Leader Innocan Pharma's Q3: 174% YoY Revenue Growth
Patricio Liddle
Tuesday, May 28, 2024
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
Patricio Liddle
Tuesday, April 23, 2024
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Jelena Martinovic
Tuesday, April 02, 2024
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Patricio Liddle
Tuesday, February 13, 2024
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Jelena Martinovic
Monday, October 23, 2023
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
Jelena Martinovic
Thursday, September 21, 2023
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Jelena Martinovic
Monday, August 28, 2023
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Nicolás Jose Rodriguez
Friday, August 25, 2023
Cannabis Stock Gainers And Losers From August 25, 2023
Benzinga Insights
Monday, August 21, 2023
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Benzinga Insights
Thursday, August 17, 2023
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Benzinga Insights
Monday, August 14, 2023
Cannabis Stock Gainers And Losers From August 14, 2023
Benzinga Insights
Friday, August 11, 2023
Cannabis Stock Gainers And Losers From August 11, 2023
Benzinga Insights
Friday, August 04, 2023
Innocan Pharma Secures $1.4M Via Private Placement
Vuk Zdinjak
Tuesday, July 25, 2023
Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price
Vuk Zdinjak
Friday, July 21, 2023
Cannabis Stock Movers For July 21, 2023
Benzinga Insights
Thursday, June 01, 2023
Innocan Pharma Q1 Revenue Grows 500% YoY, Here Is What You Need To Know
Vuk Zdinjak
Wednesday, April 19, 2023
Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know
Vuk Zdinjak
Tuesday, February 21, 2023
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
Vuk Zdinjak
Tuesday, November 29, 2022
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
Vuk Zdinjak
Tuesday, November 02, 2021
4 CBD Stocks in the Canadian Capital Market
Josh Horowitz
-
Sponsored
Tuesday, December 01, 2020
Innocan Pharma's CBD Treatments Progress Into The Next Stage
Josh Horowitz
Monday, June 03, 2019
Nabis Holdings Acquires 49% Stake In Israel-Based Cannova Medical
Alex Oleinic
Sunday, April 07, 2019
This Week's Cannabis News: The FDA And CBD, The STATES Act, Cresco And Origin House, Europe And High Times
Javier Hasse
Thursday, April 04, 2019
Nabis Execs Talks $26M Raise: 'It Takes A Unique Product Offering, Solid Development, Branding And Distribution'
Javier Hasse
Sunday, February 03, 2019
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Javier Hasse
